Merck KGaA (MKKGY)
| Market Cap | 54.39B |
| Revenue (ttm) | 24.92B |
| Net Income (ttm) | 3.36B |
| Shares Out | n/a |
| EPS (ttm) | 7.74 |
| PE Ratio | 16.18 |
| Forward PE | 12.30 |
| Dividend | 0.34 (1.33%) |
| Ex-Dividend Date | Apr 29, 2025 |
| Volume | 25,617 |
| Average Volume | 105,923 |
| Open | 25.16 |
| Previous Close | 25.46 |
| Day's Range | 25.00 - 25.31 |
| 52-Week Range | 24.32 - 37.66 |
| Beta | 0.61 |
| RSI | 47.44 |
| Earnings Date | Nov 13, 2025 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and test... [Read more]
Full Company ProfileFinancial Performance
In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.
Financial numbers in EUR Financial StatementsNews
Merck Foundation CEO Meets the First Lady of Cabo Verde & 13 African and Asian First Ladies of Africa at the Merck Foundation First Ladies Initiative Summit 2025
Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 recently. It was inaugurated by Prof. Dr. Frank...
Merck Foundation CEO Meets Zimbabwe First Lady & 13 First Ladies of Africa and Asia at the 7th Edition of Merck Foundation First Ladies Initiative Summit to Discuss the Strategy to Build Healthcare Capacity and Support Girl Education
Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 recently. Business Wire India Merck Foundation,...
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovativ...
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drug...
Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Ch...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Merck KGaA 2025 Q2 - Results - Earnings Call Presentation
Merck KGaA (MKGAF) Q2 2025 Earnings Call Transcript
Merck KGaA gives Q2 results
Merck Foundation CEO and First Ladies of Africa to Call for Action to Build Healthcare and Media Capacity, Break Infertility Stigma and Support Girl Education in 2026 and Beyond
Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 on 19th and 20th June. Business Wire India Merc...
Merck Foundation Provides Training for Journalists from 35 Countries During the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit
Business Wire India Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025, in presence of Merck Found...
Merck Foundation Together with African and Asian First Ladies Mark ‘World Assisted Reproductive Technology Day’ 2025 Through Their ‘More Than a Mother’ Campaign
Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World ART (Assisted Reproductive Technology) Day 2025′ together with African and Asian First Ladies, who are also the Ambassadors ...
Merck KGaA: The Undervaluation Is Now Close To 13-Year Lows
MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration
Strengthens 90-year legacy of partnership between MilliporeSigma and WashU to accelerate scientific progress Strategic academic-industry alliance aims to build robust Research & Development talent pip...
Merck KGaA gets EU nod for Ezmekly
Europe is lagging behind in AI-specific patents: Merck KGaA
Kai Beckmann, CEO of Electronics at Merck KGaA, discusses Europe's competitiveness in AI development.
MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Validated protocols across ...
Dr. Rasha Kelej Meets Mauritius President to Strengthen Partnership to Improve Access to Innovative and Equitable Healthcare and Empower Women in STEM
Senator, Dr. Rasha Kelej, CEO of Merck Foundation, the philanthropic arm of Merck KGaA Germany met HIS EXCELLENCY MR. DHARAMBEER GOKHOOL, The President of Republic of Mauritius, during a high-level me...
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for...
Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai
Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 on 19th and 20th June in Dubai, United Arab Emi...
MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant
Winner’s lead therapy targets Parkinson’s disease; platform addresses 6,000+ genetic disorders Neoclease gains access to MilliporeSigma’s technologies and expert support to scale its AI-designed gene-...
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China...
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical P...
China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (N...
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p<0.00...